Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 7/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | SPNS2 | Q8IVW8 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179637 | 0.91 | SMN1; SMN2 (0.37) | AGERHSD11B1MAPTSMN1; SMN2TP53 | |
| SCHEMBL6179907 | 0.86 | LMNA (0.36) | AGERMAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL6329377 | 0.84 | SMN1; SMN2 (0.38) | HSD11B1MAPTSMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL6174783 | 0.84 | PTGS2 (0.44) | HSD11B1MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL6176741 | 0.84 | GPR119 (0.41) | HSD11B1MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL6173846 | 0.80 | AGER (0.54) | AGERHSD11B1SPNS2MAPTSMN1; SMN2 | |
| SCHEMBL4457149 | 0.79 | AGER (0.51) | AGERHSD11B1SPNS2MAPTSMN1; SMN2 | |
| SCHEMBL6178027 | 0.74 | NPC1 (0.50) | NPC1RAB9AGSK3B | |
| SCHEMBL9185281 | 0.70 | IDO1 (0.42) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6177327 | 0.69 | SPNS2 (0.43) | AGERHSD11B1SPNS2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956050-B2 | Imidazole compounds as anti-inflammatory and analgesic agents | PFIZER, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1494667-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | HIRANO MISATO (JP) | 2003-11-27 | — | — | US | disclosed |
| WO-2003086390-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, PTGES | AGER 4034/4885HSD11B1 88/4885SPNS2 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.